《柳叶刀肿瘤学2025》的更正：4月14日在线发布。00150年https://doi.org/10.1016/s1470 - 2045 (25)

The Lancet Oncology Pub Date : 2025-04-30 DOI:10.1016/s1470-2045(25)00238-4

{"title":"《柳叶刀肿瘤学2025》的更正：4月14日在线发布。00150年https://doi.org/10.1016/s1470 - 2045 (25)","authors":"","doi":"10.1016/s1470-2045(25)00238-4","DOIUrl":null,"url":null,"abstract":"Pe M, Voltz-Girolt C, Bell J, et al. Using patient-reported outcomes and health-related quality of life data in regulatory decisions on cancer treatment: highlights from an EMA-EORTC workshop. Lancet Oncol 2025; published online April 14. https://doi.org/10.1016/S1470-2045(25)00150-0—In this Essay, the affiliation of Jill Bell should have been Evinova an AstraZeneca Group, Gaithersburg, MD, USA only, and the affiliation of Jan Bogaerts should have been European Organisation for Research and Treatment of Cancer, Brussels, Belgium only. These corrections have been made to the online version as of April 30, 2025, and the printed version is correct.","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"35 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Correction to Lancet Oncol 2025: published online April 14. https://doi.org/10.1016/S1470-2045(25)00150\",\"authors\":\"\",\"doi\":\"10.1016/s1470-2045(25)00238-4\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Pe M, Voltz-Girolt C, Bell J, et al. Using patient-reported outcomes and health-related quality of life data in regulatory decisions on cancer treatment: highlights from an EMA-EORTC workshop. Lancet Oncol 2025; published online April 14. https://doi.org/10.1016/S1470-2045(25)00150-0—In this Essay, the affiliation of Jill Bell should have been Evinova an AstraZeneca Group, Gaithersburg, MD, USA only, and the affiliation of Jan Bogaerts should have been European Organisation for Research and Treatment of Cancer, Brussels, Belgium only. These corrections have been made to the online version as of April 30, 2025, and the printed version is correct.\",\"PeriodicalId\":22865,\"journal\":{\"name\":\"The Lancet Oncology\",\"volume\":\"35 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-04-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Lancet Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/s1470-2045(25)00238-4\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Lancet Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/s1470-2045(25)00238-4","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

李建军，李建军，李建军，等。在癌症治疗的监管决策中使用患者报告的结果和与健康相关的生活质量数据：EMA-EORTC研讨会的亮点柳叶刀肿瘤学杂志2025；4月14日在网上发表。https://doi.org/10.1016/S1470-2045(25)00150-0 -在这篇文章中，吉尔·贝尔的隶属关系应该是Evinova的阿斯利康集团，盖瑟斯堡，马里兰州，只有美国，和Jan Bogaerts的隶属关系应该是欧洲组织的研究和治疗癌症，布鲁塞尔，比利时只有。这些更正已经在2025年4月30日对网络版进行了修改，印刷版是正确的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Correction to Lancet Oncol 2025: published online April 14. https://doi.org/10.1016/S1470-2045(25)00150

Pe M, Voltz-Girolt C, Bell J, et al. Using patient-reported outcomes and health-related quality of life data in regulatory decisions on cancer treatment: highlights from an EMA-EORTC workshop. Lancet Oncol 2025; published online April 14. https://doi.org/10.1016/S1470-2045(25)00150-0—In this Essay, the affiliation of Jill Bell should have been Evinova an AstraZeneca Group, Gaithersburg, MD, USA only, and the affiliation of Jan Bogaerts should have been European Organisation for Research and Treatment of Cancer, Brussels, Belgium only. These corrections have been made to the online version as of April 30, 2025, and the printed version is correct.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

The Lancet Oncology

自引率

0.00%

发文量